Mepolizumab does not prevent all aspirin-induced reactions in patients with aspirin-exacerbated respiratory disease: A case series

Abstract

Aspirin-exacerbated respiratory disease (AERD) is a syndrome that includes nasal polyposis, asthma, and nonsteroidal anti-inflammatory drug sensitivity. This clinical triad is seen in about 7% of adults with asthma, and in about 15% of those with severe asthma,1 with the average age of onset being 34 years. A positive aspirin-induced reaction during a provocative aspirin challenge is the current standard for confirmative diagnosis.2 Aspirin desensitization, followed by initiation of daily high-dose aspirin therapy, is often used to help reduce nasal polyposis and asthma symptoms in these patients.